The majority of canine cancer treatments rely on the use of human generic chemotherapeutics. The clinical responses to these therapeutics for the most common canine cancers have remained static for the past 10-20 years.
Focusing on canine B-cell lymphoma in particular, the standard of care for
dogs with high grade lymphoma over the last 35 years has ranged from
single agent protocols to combination chemotherapy regimens of variable
duration. However, the response to chemotherapy is often sub-optimal
with recurrent or refractory disease representing a significant clinical
Immuno-oncology innovations are starting to make their way to veterinary
oncology but remain limited with extremely sparse supporting data.